Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tavocept in combination with cisplatin and either docetaxel or paclitaxel · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Placebo in combination with cisplatin and either paclitaxel or docetaxel |
| Tavocept (BNP7787) | ACTIVE_COMPARATOR | Tavocept (BNP7787) in combination with cisplatin and either docetaxel or paclitaxel |
| Name | Type | Description |
|---|---|---|
| Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel | DRUG | Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Tavocept(BNP7787) 18.4gm/m2 IV every 3 weeks |
| Placebo in combination with cisplatin and docetaxel or paclitaxel | DRUG | Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Placebo IV every 3 weeks |
Inclusion Criteria: * Confirmed histopathological diagnosis of inoperable advanced primary adenocarcinoma (including bronchioalveolar cell carcinoma) of the lung * No prior systemic treatment for non-small cell lung cancer including chemotherapy, immunotherapy, hormonal therapy, targeted therapies ...
Top 20 of 90 competitors
Tavocept is being studied in combination with cisplatin and either docetaxel or paclitaxel for patients with newly diagnosed or relapsed advanced primary adenocarcinoma of the lung, a form of non-small cell lung cancer. It is an investigational small molecule developed by Lantern Pharma Inc. (LTRN) and has reached Phase 3 testing.
Tavocept is being developed by Lantern Pharma Inc., which trades under the ticker LTRN. The company is advancing the small molecule in combination with cisplatin and either docetaxel or paclitaxel for advanced primary adenocarcinoma of the lung, a non-small cell lung cancer indication.
Tavocept is in Phase 3 development. A randomized, double-blind, placebo-controlled Phase 3 trial has been completed, and no trials of the combination regimen are currently active. Tavocept is investigational and has not been established as an approved therapy for non-small cell lung cancer.
Tavocept has been evaluated in the Phase 3 trial NCT00966914, titled a study of Tavocept versus placebo in patients with newly diagnosed or relapsed advanced primary adenocarcinoma of the lung treated with docetaxel or paclitaxel plus cisplatin. The trial enrolled 540 patients across the United States, Bulgaria, Poland, Romania, Russia, and Ukraine, and it is completed.
Yes. Tavocept is also known as BNP7787. The combination regimen referenced in its clinical program is Tavocept (BNP7787) in combination with cisplatin and either docetaxel or paclitaxel, so searches using either name refer to the same investigational agent developed by Lantern Pharma Inc. (LTRN).
The Phase 3 trial NCT00966914 was randomized, double-blind, and placebo-controlled, enrolling 540 patients aged 18 years and older of all sexes. It compared Tavocept against placebo in patients with newly diagnosed or relapsed advanced primary adenocarcinoma of the lung who were treated with docetaxel or paclitaxel plus cisplatin. The study is completed.